Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Pemigatinib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2023
Same author

Epcoritamab: First Approval.

Drugs·2023
Same author

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023
Same author

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023

Related Experiment Video

Updated: Jun 22, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Risedronate on two consecutive days per month.

James E Frampton1

  • 1Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|May 30, 2009
PubMed
Summary
This summary is machine-generated.

Risedronate 75 mg taken twice monthly is as effective as daily dosing for postmenopausal osteoporosis treatment. This new regimen maintains bone mineral density and has a similar safety profile.

Related Experiment Videos

Last Updated: Jun 22, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Clinical Trials

Background:

  • Postmenopausal osteoporosis is a significant health concern.
  • Optimizing patient adherence to bisphosphonate therapy is crucial for treatment effectiveness.
  • Risedronate is an effective oral bisphosphonate for osteoporosis management.

Purpose of the Study:

  • To evaluate the noninferiority of a new risedronate dosing regimen (75 mg on two consecutive days each month, 2CDM) compared to daily risedronate (5 mg once daily).
  • To assess the efficacy and tolerability of risedronate 75 mg 2CDM in postmenopausal women with osteoporosis.

Main Methods:

  • A 2-year, randomized, double-blind, parallel-group, multinational trial.
  • Involved 1229 postmenopausal women diagnosed with osteoporosis.
  • Compared risedronate 75 mg 2CDM to risedronate 5 mg once daily for 12 months.

Main Results:

  • Risedronate 75 mg 2CDM was noninferior to 5 mg once daily in improving lumbar spine bone mineral density (BMD) at 12 months (mean increases of 3.4% vs. 3.6%).
  • Similar improvements in hip BMD and reductions in bone turnover markers were observed between groups.
  • No significant difference in the incidence of new vertebral fractures or upper gastrointestinal adverse events was found.

Conclusions:

  • The risedronate 75 mg 2CDM regimen is a viable, noninferior alternative to daily dosing for treating postmenopausal osteoporosis.
  • This dosing schedule offers potential benefits for patient adherence and persistence.
  • The safety and efficacy profile of the 2CDM regimen is comparable to the daily regimen.